AMENDMENTS

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A pharmaceutical compound according to Formula I,



FORMULA I

wherein R1, R2, R3 and R4 are selected from the group consisting of a straight or branched chain alkyl group having 1 to 6 carbons substitutes with one or more Ra groups, a benzyl group, a phenyl group which is substituted with one or two Rb groups, and a benzyl group which is substituted with one or two Rb groups;

wherein R1, R2, R3 and R4 are selected from the group consisting of halogen, $-NO_2$, $-OCH_3$, $-OCH_2CH_3$, $-CH(CH_3)_2$, [[$-(CH_2)_nOH$]]$-(CH_2)OH$, $-(CH_2)_2OH$, $-(CH_2)_3OH$, $-(CH_2)_4OH$, [[$-(CH_2)_nNH$,]]$-(CH_2)NH_2$, $-(CH_2)_2NH_2$, $-(CH_2)_3NH_2$, $-(CH_2)_4NH_2$, $-(CH_2)_5NH_2$, $-CH_2CH_2N(CH_3)_2$, $-CH_2CH_2NH(CH_2)_2OH$, cyclopentane, 2,3-$(CH_3)_2$-cyclohexane, -S-Rc, -O-CO-Rd, -N-Re, -CO-Rf, -CONH-Rg; and

wherein Ra, Rb, Rc, Rd, Re, Rf, Rg are selected from the group consisting of a straight or branched chain alkyl group having 1 to 6 carbons, $-NO_2$, $-OCH_3$, $-OCH_2CH_3$, $-CH(CH_3)_2$, [[$-(CH_2)_nOH$]]$-(CH_2)OH$, $-(CH_2)_2OH$, $-(CH_2)_3OH$, $-(CH_2)_4OH$, [[$-(CH_2)_nNH$,]]$-(CH_2)NH_2$, $-(CH_2)_2NH_2$, $-(CH_2)_3NH_2$, $-(CH_2)_4NH_2$, $-(CH_2)_5NH_2$, $-CH_2CH_2N(CH_3)_2$, $-CH_2CH_2NH(CH_2)_2OH$, cyclopentane, 2,3-$(CH_3)_2$-cyclohexane, -S-, -OCO-, -N-, -CO-, -CONH-.

2. (Original) The compound according to claim 1, wherein R1, R2, R3 and R4 represent a substituted phenyl, benzyl, ethylphenyl, cyclopentane, and 2,3-$(CH_3)_2$-cyclohexane groups selected from the group consisting of 2-$CH_3C_6H_4$, 3-$CH_3C_6H_4$, 4-$CH_3C_6H_4$, 2-OHC_6H_4, 3-OHC_6H_4, 4-OHC_6H_4, 2-ClC_6H_4, 3-ClC_6H_4, 4-ClC_6H_4, 2-$NO_2C_6H_4$, 3-$NO_2C_6H_4$, 4-$NO_2C_6H_4$, 2-$NH_2C_6H_4$, 3-$NH_2C_6H_4$, 4-$NH_2C_6H_4$, and 2,4-$Cl_2C_6H_3$.

3. (Original) The compound according to claim 1, wherein R1, R2, R3 and R4 represent a substituted alkyl group selected from the group consisting of CH_2Br, CH_2Cl, CH_2OH, $C(CH_3)_3$, $(CH_2)_2OH$, $(CH_2)_3OH$, $(CH_2)_4OH$, CH_2NH_2, $(CH_2)_2NH_2$, $(CH_2)_3NH_2$, $(CH_2)_4NH_2$, $(CH_2)_5NH_2$, $CH_2N(CH_3)_2$, $(CH_2)_2N(CH_3)_2$, $(CH_2)_2NH(CH_2)_2OH$, $(CH_2)_3NH(CH_2)_2OH$, $(CH_2)_2NHCH_2OH$, $(CH_2)_3NHCH_2OH$, $CH_2CH(CH_3)_2$, $CHCl_2$, $CH(CH_3)Cl$, $(CH_2)_2Cl$, $(CH_2)_3Cl$, $(CH_2)_3Br$, $(CH_2)_4Br$, and $(CH_2)_4Cl$.

4. [Cancelled]

5. [Cancelled]

6. [Cancelled]

7. [Cancelled]

8. [Cancelled]

9. [Cancelled]

10. (Original) A compound having the chemical structure of Formula I,



FORMULA I

wherein R1, R2, R3 and R4 represent cyclopentane, cyclohexane, $-C_6H_5$, $-CH_2C_6H_5$, or $-CH_2CH_2C_6H_5$, group having one, two or three substituents which is selected from the group of halogen, OH, CH_3, OCH_3, NH_2, and NO_2.

11. (Original) A compound having the chemical structure of Formula I,



FORMULA I

wherein R1, R2, R3 and R4 represent -S-, -O-CO-, -N-, -CO-, and -CONH-, consisting of a straight or branched chain alkyl group having 1 to 6 carbons, and CH_2Br, CH_2Cl, CH_2OH, $C(CH_3)_3$, $(CH_2)_2OH$, $(CH_2)_3OH$, $(CH_2)_4OH$, CH_2NH_2, $(CH_2)_2NH_2$, $(CH_2)_3NH_2$, $(CH_2)_4NH_2$, $(CH_2)_5NH_2$, $CH_2N(CH_3)_2$, $(CH_2)_2N(CH_3)_2$, $(CH_2)_2NH(CH_2)_2OH$, $(CH_2)_3NH(CH_2)_2OH$, $(CH_2)_2NHCH_2OH$, $(CH_2)_3NHCH_2OH$, $CH_2CH(CH_3)_2$, $CHCl_2$, $CH(CH_3)Cl$, $(CH_2)_2Cl$, $(CH_2)_3Cl$, $(CH_2)_3Br$, $(CH_2)_4Br$, and $(CH_2)_4Cl$.

12. (Cancelled)

13. (Original) A method for anti-cancer treatment, comprising administering a therapeutically effective amount of a pharmaceutical compounds according to claim 11 or a pharmaceutically acceptable salt of said compound and optionally a pharmaceutical carrier to a patient in need of such treatment.

14. (Original) A method for treating abnormal proliferation, comprising administering a therapeutically effective amount of a pharmaceutical compounds according to claim 11 or a pharmaceutically acceptable salt of said compound and optionally a pharmaceutical carrier to a patient in need of such treatment.

15. (Original) A method for enhancing an anti-oxidation affect, comprising administering a therapeutically effective amount of a pharmaceutical compounds according to claim 11 or a pharmaceutically acceptable salt of said compound and optionally a pharmaceutical carrier to a patient in need of such treatment.

16. (Original) A method for enhancing human telomerase activity, comprising administering a therapeutically effective amount of a pharmaceutical compounds according to claim 11 or a pharmaceutically acceptable salt of said compound and optionally a pharmaceutical carrier to a patient in need of such treatment.

17. (Original) A method for stem cell research, comprising administering a therapeutically effective amount of a pharmaceutical compounds according to claim 11 or a pharmaceutically acceptable salt of said compound and optionally a pharmaceutical carrier to a patient in need of such treatment.

18. (Original) A method for enhancing tissue engineering application, comprising administering a therapeutically effective amount of a pharmaceutical compounds according to claim 11 or a pharmaceutically acceptable salt of said compound and optionally a pharmaceutical carrier to a patient in need of such treatment.

19. [Cancelled]

20. [Cancelled]

21. [Cancelled]

22. [Cancelled]

23. [Cancelled]

24. [Cancelled]

25. [Cancelled]